



## XTL Biopharmaceuticals Announces Corporate Presentations to be Held Today, Monday, November 6, 2006

- Rodman & Renshaw 8<sup>th</sup> Annual Healthcare Conference --
- CIBC World Markets 17<sup>th</sup> Annual Healthcare Conference --

### For Immediate Release

**NEW YORK, NEW YORK, November 6, 2006** – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 8<sup>th</sup> Annual Healthcare Conference and the CIBC World Markets 17<sup>th</sup> Annual Healthcare Conference. Both presentations will be held today, as follows:

**Rodman & Renshaw 8<sup>th</sup> Annual Healthcare Conference** – 10:15 am EST at the New York Palace Hotel in New York City. A live webcast of Mr. Bentsur's presentation will be available at <http://www.wsw.com/webcast/rrshq10/xtl.ln/>. An archived version of the webcast will be available following the conclusion of the live presentation.

**CIBC World Markets 17<sup>th</sup> Annual Healthcare Conference** – 12:55 pm EST at the Waldorf Astoria Hotel in New York City. A live webcast of Mr. Bentsur's presentation will be available at <http://www.veracast.com/webcasts/cibcwm/healthcare06/54109276.cfm>. An archived version of the webcast will be available following the conclusion of the live presentation.

### **ABOUT XTL BIOPHARMACEUTICALS LTD.**

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

### *Contact:*

Ron Bentsur, Chief Executive Officer  
Tel: +1-(212)-531-5960